Browsing Tag
Small cell lung cancer
21 posts
Why BeOne Medicines (ONC) just strengthened its China oncology play with Imdelltra approval
BeOne Medicines wins China approval for Amgen’s Imdelltra in lung cancer. Read why this matters for ONC, competition, and China oncology growth.
Avacta (AIM: AVCT) opens AVA6103 Phase 1: Can sustained-release engineering salvage exatecan’s clinical legacy?
Avacta Therapeutics opens Phase 1 enrollment for AVA6103 exatecan PDC at two US oncology centers. Early data expected H2 2026. Read what it means for AVCT investors.
Is this the most promising DLL3-targeting therapy yet? Zai Lab advances ADC into Phase 3
Zai Lab’s DLL3-targeting ADC for small cell lung cancer shows high brain metastasis activity; global Phase 3 trial now underway. Explore the data and future impact.
Can ifinatamab deruxtecan redefine treatment for late-stage small cell lung cancer? Here’s what the trial shows
Discover how ifinatamab deruxtecan delivered a 48% objective response rate in pretreated ES-SCLC. Read on for trial results and next steps.
Phanes Therapeutics’ PT217 receives FDA orphan drug designation for neuroendocrine carcinoma
Phanes Therapeutics, Inc., a clinical-stage biotechnology company dedicated to advancing oncology treatments, has achieved a significant milestone with…
AstraZeneca’s Imfinzi demonstrates significant survival benefits in Phase 3 ADRIATIC trial
In a significant advancement for cancer treatment, AstraZeneca’s Imfinzi (durvalumab) has emerged as the first and only immunotherapy…
Merck to acquire Harpoon Therapeutics for $680m to strengthen oncology pipeline
Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Harpoon Therapeutics, Inc. (Nasdaq: HARP)…
LIBRETTO-431 study: Lilly’s Retevmo emerges as potential first-line treatment for RET fusion-positive NSCLC
Eli Lilly and Company (NYSE: LLY) has unveiled top-line results from the LIBRETTO-431 study, which focused on the…
Exscientia begins enrollment for Phase 1/2 cancer trial of CDK7 inhibitor
AI-driven precision medicine company Exscientia has initiated enrollment for its Phase 1/2 “ELUCIDATE” study, marking the first trial…
Eagle Pharmaceuticals gets Pemfexy FDA approval for NSCLC
Eagle Pharmaceuticals has secured an additional indication for Pemfexy (pemetrexed injection) in the US, marking the fifth indication…